A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Roman Rohrbach et al.|Nature Medicine|2023Cited by 226
Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCRNicola Schanda, Anita Schmitt|Cells|2021Cited by 41
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25
Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responsesMichael Schmitt, Jochen Greiner, Anita Schmitt et al.|Theranostics|2017Cited by 11
Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative DonorMichael Schmitt, Jochen Greiner, Anita Schmitt et al.|Blood|2016Cited by 1